Sprionolactone for Adult Female Acne (SAFA): pragmatic multi-centre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of sprionolactone for moderate or severe persistent acne in women

Project Details

StatusActive
Effective start/end date1/04/1831/08/22

Funding

  • National Institute for Health Research: £65,532.00